LP
ALDR

LMR Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

LMR Partners’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-19,345
Closed -$483K – 544
2016
Q2 		$483K Buy
+19,345
New +$523K 0.07% 289

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's ALDR Position: Q3 2016 in Review

LMR Partners sold out of Alder Biopharmaceuticals (ALDR) in Q3 2016, closing a stake of 19,345 shares — an estimated $483K sold.

LMR Partners first reported a position in ALDR in Q2 2016 and held it in 1 quarter. The position peaked at $483K in Q2 2016. 159 funds tracked by Wall St. Rank hold ALDR as of Q3 2016.

  • LMR Partners reported no remaining Alder Biopharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • LMR Partners sold 19,345 Alder Biopharmaceuticals shares in Q3 2016, an estimated $483K.
  • LMR Partners first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 1 quarter.
  • LMR Partners's Alder Biopharmaceuticals position peaked at $483K in Q2 2016.
  • 159 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2016.

Based on LMR Partners's 13F filing for Q3 2016, filed 1 Nov 2016.